F-18-fluoro-2-deoxyglucose positron emission tomography (PET) and PET/computed tomography imaging in primary staging of patients with malignant melanoma: A systematic review

Systematic Reviews

Volumn 1, Issue 1, 2012, Pages

  Schröer Günther, Milly A ^a   Wolff, Robert F ^b   Westwood, Marie E ^b   Scheibler, Fülöp J ^a   Schürmann, Christoph ^a   Baumert, Brigitta G ^d   Sauerland, Stefan ^a   Kleijnen, Jos ^b,c  

^a INSTITUTE FOR QUALITY AND EFFICIENCY IN HEALTH CARE IQWIG   (Germany)

^b KLEIJNEN SYSTEMATIC REVIEWS LTD   (United Kingdom)

^c MAASTRICHT UNIVERSITY   (Netherlands)

^d MAASTRICHT UNIVERSITY   (Netherlands)

Author keywords

Computed tomography; Esophageal neoplasms; Positron emission tomography; Recurrence; Staging; Systematic review

Indexed keywords

FLUORODEOXYGLUCOSE F 18; DIAGNOSTIC AGENT; RADIOPHARMACEUTICAL AGENT;

ARTICLE; CANCER STAGING; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DIAGNOSTIC ACCURACY; HUMAN; INTERMETHOD COMPARISON; LIVER METASTASIS; LUNG METASTASIS; MELANOMA; POSITRON EMISSION TOMOGRAPHY; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; SYSTEMATIC REVIEW; PATHOLOGY; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SCINTISCANNING; SKIN TUMOR;

FLUORODEOXYGLUCOSE F18; HUMANS; MELANOMA; NEOPLASM STAGING; POSITRON-EMISSION TOMOGRAPHY; POSITRON-EMISSION TOMOGRAPHY AND COMPUTED TOMOGRAPHY; RADIOPHARMACEUTICALS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SKIN NEOPLASMS;

MLCS; MLOWN;

EID: 84876185766     PISSN: None     EISSN: 20464053     Source Type: Journal    
DOI: 10.1186/2046-4053-1-62     Document Type: Article

References (45)

1. National Collaborating Centre for Cancer Guidance on Cancer Services: Improving Outcomes for People with Skin Tumours including Melanoma; The Manual, Vol. 2009 2006, National Institute for Health and Clinical Excellence, London, National Collaborating Centre for Cancer.
2. Garbe C, Peris K, Hauschild A, Saiag P, Midddleton M, Spatz A, Grob JJ, Malvehy J. Diagnosis and treatment of melanoma: European consensus-based interdisciplinary guideline. Eur J Cancer Clin Oncol 2010, 46:270-283.
3. Diagnosis and Treatment of Melanoma: European Consensus-based Interdisciplinary Guideline. http://www.ecco-org.eu/binarydata.aspx?type=doc/diagnosis_and_treatment_of_melanoma.pdf.
4. Dummer R, Hauschild A, Pentheroudakis G. Cutaneous malignant melanoma: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol 2009, 20(Suppl 4):129-131.
5. Saiag P, Bosquet L, Guillot B, Verola O, Avril MF, Bailly C, Cupissol D, Dalac S, Danino A, Dréno B, Grob JJ, Leccia MT, Renaud-Vilmer C, Négrier S, de Dermatologie SF. Management of adult patients with cutaneous melanoma without distant metastasis: 2005 update of the French standards, options and recommendations guidelines; summary report. Eur J Dermatol 2007, 17:325-331.
6. Marsden JR, Newton-Bishop JA, Burrows L, Cook M, Corrie PG, Cox NH, Gore ME, Lorigan P, MacKie R, Nathan P, Peach H, Powell B, Walker C, British Association of Dermatologists Clinical Standards Unit Revised U.K. guidelines for the management of cutaneous melanoma. Br J Dermatol 2010, 163:238-256. 10.1111/j.1365-2133.2010.09883.x, 20608932, British Association of Dermatologists Clinical Standards Unit.
7. Allgemeine Methoden: Version 4.0. https://www.iqwig.de/download/IQWiG_Entwurf_Methoden_Version_4-0.pdf.
8. Positronenemissionstomographie (PET und PET/CT) bei malignen Melanom. https://www.iqwig.de/download/D06-01F_Abschlussbericht_PET_und_PET-CT_bei_malignem_Melanom.pdf.
9. Oxman AD, Guyatt GH. Validation of an index of the quality of review articles. J Clin Epidemiol 1991, 44:1271-1278. 10.1016/0895-4356(91)90160-B, 1834807.
10. Oxman AD, Guyatt GH, Singer J, Goldsmith CH, Hutchison BG, Milner RA, Streiner DL. Agreement among reviewers of review articles. J Clin Epidemiol 1991, 44:91-98.
11. Whiting P, Rutjes AW, Reitsma JB, Bossuyt PM, Kleijnen J. The development of QUADAS: a tool for the quality assessment of studies of diagnostic accuracy included in systematic reviews. BMC Med Res Methodol 2003, 3:25. 10.1186/1471-2288-3-25, 305345, 14606960.
12. Whiting PF, Rutjes AW, Westwood ME, Mallett S, Deeks JJ, Reitsma JB, Leeflang MM, Sterne JA, Bossuyt PM. QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies. Ann Intern Med 2011, 155:529-536.
13. Clopper CJ, Pearson ES. The use of confidence or fiducial limits illustrated in the case of the binominal. Biometrika 1934, 26:404-413.
14. Jiménez-Requena F, Delgado-Bolton RC, Fernandez-Perez C, Gambhir SS, Schwimmer J, Perez-Vazquez JM, Carreras-Delgado JL. Meta-analysis of the performance of 18F-FDG PET in cutaneous melanoma. Eur J Nucl Med Mol Imaging 2010, 37:284-300. 10.1007/s00259-009-1224-8, 2886141, 19727717.
15. Krug B, Crott R, Lonneux M, Baurain JF, Pirson AS, Vander Borght T. Role of PET in the initial staging of cutaneous malignant melanoma: systematic review. Radiology 2008, 249:836-844. 10.1148/radiol.2493080240, 19011184.
16. Mijnhout GS, Hoekstra OS, Van Tulder MW, Teule GJ, Deville WL. Systematic review of the diagnostic accuracy of 18F-fluorodeoxyglucose positron emission tomography in melanoma patients. Cancer 2001, 91:1530-1542. 10.1002/1097-0142(20010415)91:8<1530::AID-CNCR1162>3.0.CO;2-#, 11301402.
17. Xing Y, Bronstein Y, Ross MI, Askew RL, Lee JE, Gershenwald JE, Royal R, Cormier JN. Contemporary diagnostic imaging modalities for the staging and surveillance of melanoma patients: a meta-analysis. J Natl Cancer Inst 2011, 103:129-142. 10.1093/jnci/djq455, 3022618, 21081714.
18. Acland KM, Healy C, Calonje E, O'Doherty M, Nunan T, Page C, Higgins E, Russell-Jones R. Comparison of positron emission tomography scanning and sentinel node biopsy in the detection of micrometastases of primary cutaneous malignant melanoma. J Clin Oncol 2001, 19:2674-2678.
19. Belhocine T, Pierard G, De Labrassinne M, Lahaye T, Rigo P. Staging of regional nodes in AJCC stage I and II melanoma: 18FDG PET imaging versus sentinel node detection. Oncologist 2002, 7:271-278. 10.1634/theoncologist.7-4-271, 12185291.
20. Fink AM, Holle-Robatsch S, Herzog N, Mirzaei S, Rappersberger K, Lilgenau N, Jurecka W, Steiner A. Positron emission tomography is not useful in detecting metastasis in the sentinel lymph node in patients with primary malignant melanoma stage I and II. Melanoma Res 2004, 14:141-145. 10.1097/00008390-200404000-00011, 15057045.
21. Klein M, Freedman N, Lotem M, Marciano R, Moshe S, Gimon Z, Chisin R. Contribution of whole body F-18-FDG-PET and lymphoscintigraphy to the assessment of regional and distant metastases in cutaneous malignant melanoma: a pilot study. Nuklearmedizin 2000, 39:56-61.
22. Rinne D, Baum RP, Hor G, Kaufmann R. Primary staging and follow-up of high risk melanoma patients with whole-body 18F-fluorodeoxyglucose positron emission tomography: results of a prospective study of 100 patients. Cancer 1998, 82:1664-1671. 10.1002/(SICI)1097-0142(19980501)82:9<1664::AID-CNCR11>3.0.CO;2-2, 9576286.
23. Singh B, Ezziddin S, Palmedo H, Reinhardt M, Strunk H, Tuting T, Biersack HJ, Ahmadzadehfar H. Preoperative 18F-FDG-PET/CT imaging and sentinel node biopsy in the detection of regional lymph node metastases in malignant melanoma. Melanoma Res 2008, 18:346-352. 10.1097/CMR.0b013e32830b363b, 18781133.
24. Eigtved A, Andersson AP, Dahlstrom K, Rabol A, Jensen M, Holm S, Sorensen SS, Drzewiecki KT, Hojgaard L, Friberg L. Use of fluorine-18 fluorodeoxyglucose positron emission tomography in the detection of silent metastases from malignant melanoma. Eur J Nucl Med 2000, 27:70-75. 10.1007/PL00006666, 10654150.
25. Hafner J, Schmid MH, Kempf W, Burg G, Kunzi W, Meuli-Simmen C, Neff P, Meyer V, Mihic D, Garzoli E, Jungius KP, Seifert B, Dummer R, Steinert H. Baseline staging in cutaneous malignant melanoma. Br J Dermatol 2004, 150:677-686. 10.1111/j.0007-0963.2004.05870.x, 15099363.
26. Vereecken P, Laporte M, Petein M, Steels E, Heenen M. Evaluation of extensive initial staging procedure in intermediate/high-risk melanoma patients. J Eur Acad Dermatol Venereol 2005, 19:66-73. 10.1111/j.1468-3083.2004.01130.x, 15649194.
27. Crippa F, Leutner M, Belli F, Gallino F, Greco M, Pilotti S, Cascinelli N, Bombardieri E. Which kinds of lymph node metastases can FDG PET detect? A clinical study in melanoma. J Nucl Med 2000, 41:1491-1494.
28. Maubec E, Lumbroso J, Masson F, Suciu V, Kolb F, Mamelle G, Cavalcanti A, Boitier F, Spatz A, Aupérin A, Leboulleux S, Avril MF. F-18 fluorodeoxy-D-glucose positron emission tomography scan in the initial evaluation of patients with a primary melanoma thicker than 4 mm. Melanoma Res 2007, 17:147-154. 10.1097/CMR.0b013e32815c10b0, 17505260.
29. Reinhardt MJ, Kensy J, Frohmann JP, Willkomm P, Reinhold U, Grunwald F, Biersack HJ, Bender H. Value of tumour marker S-100B in melanoma patients: a comparison to 18F-FDG PET and clinical data. Nuklearmedizin 2002, 41:143-147.
30. Delgado-Bolton RC, Fernandez-Perez C, Gonzalez-Mate A, Carreras JL. Meta-analysis of the performance of 18F-FDG PET in primary tumor detection in unknown primary tumors. J Nucl Med 2003, 44:1301-1314.
31. Gould MK, Maclean CC, Kuschner WG, Rydzak CE, Owens DK. Accuracy of positron emission tomography for diagnosis of pulmonary nodules and mass lesions: a meta-analysis. JAMA 2001, 285:914-924. 10.1001/jama.285.7.914, 11180735.
32. Huebner RH, Park KC, Shepherd JE, Schwimmer J, Czernin J, Phelps ME, Gambhir SS. A meta-analysis of the literature for whole-body FDG PET detection of recurrent colorectal cancer. J Nucl Med 2000, 41:1177-1189.
33. Schwimmer J, Essner R, Patel A, Jahan SA, Shepherd JE, Park K, Phelps ME, Czernin J, Gambhir SS. A review of the literature for whole-body FDG PET in the management of patients with melanoma. Q J Nucl Med 2000, 44:153-167.
34. Aukema TS, Valdes Olmos RA, Wouters MWJM, Klop WMC, Kroon BBR, Vogel WV, Nieweg OE. Utility of preoperative 18F-FDG PET/CT and brain MRI in melanoma patients with palpable Lymph node metastases. Ann Surg Oncol 2010, 17:2773-2778. 10.1245/s10434-010-1088-y, 20422454.
35. Bastiaannet E, Wobbes T, Hoekstra OS, Van der Jagt EJ, Brouwers AH, Koelemij R, De Klerk JM, Oyen WJ, Meijer S, Hoekstra HJ. Prospective comparison of [18F]fluorodeoxyglucose positron emission tomography and computed tomography in patients with melanoma with palpable lymph node metastases: diagnostic accuracy and impact on treatment. J Clin Oncol 2009, 27:4774-4780. 10.1200/JCO.2008.20.1822, 19720925.
36. Strobel K, Dummer R, Husarik DB, Perez Lago M, Hany TF, Steinert HC. High-risk melanoma: accuracy of FDG PET/CT with added CT morphologic information for detection of metastases. Radiology 2007, 244:566-574. 10.1148/radiol.2442061099, 17641374.
37. Veit-Haibach P, Vogt FM, Jablonka R, Kuehl H, Bockisch A, Beyer T, Dahmen G, Rosenbaum S, Antoch G. Diagnostic accuracy of contrast-enhanced FDG-PET/CT in primary staging of cutaneous malignant melanoma. Eur J Nucl Med Mol Imaging 2009, 36:910-918. 10.1007/s00259-008-1049-x, 19156409.
38. Brady MS, Akhurst T, Spanknebel K, Hilton S, Gonen M, Patel A, Larson S. Utility of preoperative [18]F fluorodeoxyglucose-positron emission tomography scanning in high-risk melanoma patients. Ann Surg Oncol 2006, 13:525-532. 10.1245/ASO.2006.02.008, 16474909.
39. Fryback DG, Thornbury JR. The efficacy of diagnostic imaging. Med Decis Making 1991, 11:88-94. 10.1177/0272989X9101100203, 1907710.
40. Verfahrensordnung des Gemeinsamen Bundesausschusses. http://www.g-ba.de/downloads/62-492-634/VerfO_2012-06-21.pdf.
41. Köbberling J, Trampisch HJ, Windeler J. Memorandum for the evaluation of diagnostic measures. Clin Chem Clin Biochem 1990, 28:873-879.
42. Updating QUADAS: Evidence to Inform the Development of QUADAS-2. http://www.bris.ac.uk/quadas/resources/quadas2reportv4.pdf.
43. Altman DG, Bland JM. Statistics notes: units of analysis. BMJ 1997, 314:1874. 10.1136/bmj.314.7098.1874, 2127005, 9224131.
44. Kokoska MS, Olson G, Kelemen PR, Fosko S, Dunphy F, Lowe VJ, Stack BC. The use of lymphoscintigraphy and PET in the management of head and neck melanoma. Otolaryngol Head Neck Surg 2001, 125:213-220. 10.1067/mhn.2001.118181, 11555756.
45. Longo MI, Lazaro P, Bueno C, Carreras JL, Montz R. Fluorodeoxyglucose-positron emission tomography imaging versus sentinel node biopsy in the primary staging of melanoma patients. Dermatol Surg 2003, 29:245-248. 10.1046/j.1524-4725.2003.29058.x, 12614417.